Effects of eating behavior patterns and dietary habits on the therapeutic efficacy of Parkinson’s disease medications: from phenomena, mechanisms to clinical applications
5 affiliations
- 1Department of Cardiovascular Surgery, Shandong Medical and Pharmaceutical University Hospital , ,
- 2School of Clinic Medicine, Xiamen Medical College , ,
- 3International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba , ,
- 4School of Basic Medicine, Fujian Medical University , ,
- 5School of Dentistry, Xiamen Medical College , ,
Abstract
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder managed primarily through pharmacological dopamine replacement therapies—including levodopa (L-DOPA), dopamine receptor agonists, MAO-B inhibitors, COMT inhibitors, and novel non-dopaminergic agents like adenosine A2A receptor antagonists. However, long-term pharmacotherapy faces major challenges such as motor fluctuations, levodopa-induced dyskinesias, erratic gastrointestinal absorption, and inter-individual response variability. This review systematically synthesizes how dietary habits, macronutrient compositions, dietary patterns (e.g., Western, Eastern, Japanese, Vegetarian, Mediterranean/MIND, Ketogenic), and eating behaviors (such as restrictive eating, compulsive binge eating, and irregular meal timing) serve as critical extrinsic modulators of drug disposition and clinical performance. Multi-dimensional biological mechanisms underpin these interactions: competitive inhibition at LAT1 transporters by dietary large neutral amino acids (LNAAs), food-induced alterations in gastric emptying and hepatic/intestinal enzyme activity (e.g., CYP3A4, CYP1A2, UGT), neuroinflammatory and oxidative stress modulation via nutrient choices, and microbiota–gut–brain axis (MGBA) dynamics involving gut barrier integrity, microbial short-chain fatty acid (SCFA) production, and local bacterial enzymatic degradation of L-DOPA. In real world clinical practice, the absence of precision nutrition frameworks, protein-redistribution diets, targeted chronotherapeutic meal scheduling, and multidisciplinary nutritional support substantially hinders the effective translation of basic pharmacokinetic insights. Consequently, patients frequently encounter formidable clinical challenges, including destabilized pharmacokinetics, recurrent motor complications, and the inability to effectively delay disease progression.
Related
- NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
- The role of adipokines in the inflammatory theory of depression: mechanisms and therapeutic applications.
- The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort
- Brain functional mechanisms of acupuncture treatment for early-stage non-tremor Parkinson’s disease: a resting-state fMRI study
- Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease
BibTeX
@article{ye2026effects,
title = {{Effects of eating behavior patterns and dietary habits on the therapeutic efficacy of Parkinson’s disease medications: from phenomena, mechanisms to clinical applications}},
author = {Jingyi Ye and Sarena Jiayao Zhang and Jinzhe Guan and Zi-han Shen and Jin Wang and Ruilin Yang and Muze Huang and Zi-mo Li and Yue Lin and Hengning Gan and Shiyuan Wu and Yujiu Wang and Kaiqiang Yang},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1969279},
url = {https://europepmc.org/article/PMC/PMC13725110},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effects of eating behavior patterns and dietary habits on the therapeutic efficacy of Parkinson’s disease medications: from phenomena, mechanisms to clinical applications
AU - Jingyi Ye
AU - Sarena Jiayao Zhang
AU - Jinzhe Guan
AU - Zi-han Shen
AU - Jin Wang
AU - Ruilin Yang
AU - Muze Huang
AU - Zi-mo Li
AU - Yue Lin
AU - Hengning Gan
AU - Shiyuan Wu
AU - Yujiu Wang
AU - Kaiqiang Yang
PY - 2026
DA - 2026/10/19
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1969279
UR - https://europepmc.org/article/PMC/PMC13725110
AB - Parkinson’s disease (PD) is a common progressive neurodegenerative disorder managed primarily through pharmacological dopamine replacement therapies—including levodopa (L-DOPA), dopamine receptor agonists, MAO-B inhibitors, COMT inhibitors, and novel non-dopaminergic agents like adenosine A2A receptor antagonists. However, long-term pharmacotherapy faces major challenges such as motor fluctuations, levodopa-induced dyskinesias, erratic gastrointestinal absorption, and inter-individual response variability. This review systematically synthesizes how dietary habits, macronutrient compositions, dietary patterns (e.g., Western, Eastern, Japanese, Vegetarian, Mediterranean/MIND, Ketogenic), and eating behaviors (such as restrictive eating, compulsive binge eating, and irregular meal timing) serve as critical extrinsic modulators of drug disposition and clinical performance. Multi-dimensional biological mechanisms underpin these interactions: competitive inhibition at LAT1 transporters by dietary large neutral amino acids (LNAAs), food-induced alterations in gastric emptying and hepatic/intestinal enzyme activity (e.g., CYP3A4, CYP1A2, UGT), neuroinflammatory and oxidative stress modulation via nutrient choices, and microbiota–gut–brain axis (MGBA) dynamics involving gut barrier integrity, microbial short-chain fatty acid (SCFA) production, and local bacterial enzymatic degradation of L-DOPA. In real world clinical practice, the absence of precision nutrition frameworks, protein-redistribution diets, targeted chronotherapeutic meal scheduling, and multidisciplinary nutritional support substantially hinders the effective translation of basic pharmacokinetic insights. Consequently, patients frequently encounter formidable clinical challenges, including destabilized pharmacokinetics, recurrent motor complications, and the inability to effectively delay disease progression.
SN - 2296-861X
ER -